Status In progress
Decision Selected
Process TA
Referral date 01 March 2015

Provisional Schedule

Closing date for invited submissions / evidence submission: 3 November 2015
1st appraisal committee meeting: 16 February 2016

Project Team

Project lead Liv Gualda

Email enquiries

External Assessment Group Liverpool Reviews and Implementation Group (LRIG)


Companies sponsors Amgen
Others Department of Health
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  British Association of Skin Cancer Specialist Nurses
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Clinical Pharmacy Association
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Bristol-Myers Squibb Pharmaceutical (ipilimumab)
  Roche Products (vemurafenib)
Evidence review group Liverpool Reviews and Implementation Group (LRIG)
General commentators Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups National Institute for Health Research Technology Assessment Programme (NETSCC)?


Key events during the development of the guidance:

Date Update
28 September 2016 Expected publication
09 August 2016 - 23 August 2016 Final appraisal determination
16 March 2016 - 13 April 2016 Draft guidance: 508

For further information on our processes and methods, please see our CHTE processes and methods manual